Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3990245 | Journal of Thoracic Oncology | 2013 | 8 Pages |
Abstract
The recommended phase II dose of capecitabine is 3500 mg when given concurrently with 50.4 Gy of thoracic radiotherapy in 28 fractions and weekly docetaxel. This trimodality therapy for operable locally advanced esophageal carcinoma was very well tolerated and remarkably active. This regimen holds promise for the treatment of esophageal carcinoma and warrants further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Matthew D. MD, PhD, Bassem I. MD, Stuart R. MD, John E. MD, Mikhail MD, PhD, Jiang PhD, Jeffrey A. DO, FACP, Konstantin H. MD, James R. MD,